“…Additionally, there is limited evidence from studies in rodents and humans that pharmacological modulation of nicotinic acetylcholine receptors (nAChRs) can shift choice preference in tasks that assess cost benefit decision making (Mitchell, 2004; Reynolds et al, 2004; Dallery and Locey, 2005; Kolokotroni et al, 2011; Mendez et al, 2012; Xie et al, 2012). Finally, cholinergic signaling has been implicated in the etiology and/or treatment of numerous neuropsychiatric conditions in which cost benefit decision making is altered, including schizophrenia, Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD), Parkinson’s disease, and addiction (Clark and Robbins, 2002; Kalivas and Volkow, 2005; Karlawish et al, 2005; Thompson et al, 2007; Williams and Adinoff, 2008; Euteneuer et al, 2009; Weiler et al, 2009;Gleichgerrcht et al, 2010).…”